Don’t miss out on the next big thing in the life sciences.

Gilad Almogy, CEO & Founder, Ultima Genomics

In this Q&A, Almogy traces Ultima's origin story from a semiconductor analogy to a sequencing revolution, explains how the company's open-flow-cell architecture enables dramatically lower costs and higher throughput, and describes how those capabilities are being deployed across clinical oncology, population genomics, and large-scale biological AI. He also reflects on the culture he is building, the challenges that remain, and why he believes the convergence of sequencing, AI, and multi-omics makes this a genuine inflection point for biology and human health.